Mannatech Swings to $2.3M Profit in Q4: Cost Cuts Offset Sales Drop

Mannatech (NASDAQ: MTEX) reported a net income of $2.3 million for Q4 2024, a significant improvement from a net loss in Q4 2023, despite an 11.3% decrease in net sales to $29.0 million. The company attributed this return to profitability to strict cost management, including substantial reductions in selling and administrative expenses. For the full year 2024, Mannatech also achieved a net income of $2.5 million, compared to a loss in 2023, by mitigating the impact of declining sales and challenging economic conditions, particularly in the Asia/Pacific region.

Original reporting
Published Mar 26, 2026, 2:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 26, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MTEX
Neutral
medium confidence
Mentioned
$MTEX
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$MTEXNeutralMed
01

Why it matters

The earnings improvement may temporarily boost investor confidence, but underlying sales decline and regional challenges pose risks to sustained growth.

02

Market read

The news is moderately relevant for traders focusing on the health sector and regional markets, with immediate implications for Mannatech's stock.

03

What to watch

Potential for increased competition and regulatory changes in key markets could impact future profitability.

Relevance 6/10Timing: Immediate to short-term (next 1-3 months)

Background

Mannatech, a health and wellness company, faced losses in 2023 but managed to return to profitability in Q4 2024 through aggressive cost management.

Company-level read

Ticker impact

$MTEXNeutralMedium confidence
Context

The news reports a turnaround in Mannatech's profitability due to cost management, despite declining sales. This suggests a potential for short-term stock appreciation if the cost-cutting measures are sustainable.

Expected impact

Moderate upward movement in the short term, contingent on continued cost management success.

Evidence & confidence

The positive earnings surprise and cost-cutting measures support a potential rally, but declining sales and regional economic challenges introduce uncertainty.

Market effects

The health and wellness sector may see increased investor interest due to positive earnings reports from companies like Mannatech.

Limited regional impact; primarily affects North American and Asia/Pacific markets where Mannatech operates.

Low; Mannatech is a smaller player with limited global influence.

Counterpoint

The sales decline and regional economic challenges could outweigh the benefits of cost-cutting, leading to continued stagnation or decline in stock price.

Key entities

  • Mannatech

    A health and wellness company specializing in nutritional supplements.

  • Asia/Pacific Region

    A key market experiencing economic challenges affecting Mannatech's sales.

Related articles

$MTEXMed

Mannatech Reports Financial Results for Third Quarter 2026

MANNATECH INC (MTEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mannatech Reports Financial Results for Third Quarter 2026 (Flower Mound, Texas) November 12, 2026 - Mannatech, Incorporated (NASDAQ: MTEX ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today

$MTEXMed

Mannatech Reports Financial Results for Second Quarter 2026

MANNATECH INC (MTEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mannatech Reports Financial Results for Second Quarter 2026 (Flower Mound, Texas) August 12, 2026 - Mannatech, Incorporated (NASDAQ: MTEX ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today a

$VKTXMed

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

Viking Therapeutics (VKTX) presented clinical data from its VK2735 obesity program at ObesityWeek 2026. In a Phase 2 trial, 74% of participants improved by at least one BMI category after 13 weeks, with significant reductions in cardiometabolic markers. The company also shared baseline data from its ongoing Phase 3 VANQUISH-2 study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders.

$NVDAHigh

Jensen Huang steps down as Nvidia chief and the hunt for a new CEO begins

Nvidia announced CEO Jensen Huang's resignation and departure from the board. Colette Kress, the CFO, is interim CEO. The company thanked Huang for his contributions. No reason was given, but speculation links it to his personal scandal and national security concerns. The FBI is investigating alleged Nvidia chip exports to China via Megaspeed, where Alice Huang, tied to Jensen, is an executive. This could impact US-China relations and AI competition.

$NVDAHigh

The rise and fall of Jensen Huang

Nvidia's CEO Jensen Huang resigned after admitting an affair, with shares dropping 40% from October's peak. The board named CFO Colette Kress as interim CEO. Huang's exit raises concerns about Nvidia's key man risk and potential regulatory scrutiny, especially regarding US-China AI rivalry. The company's stock fell to $148.80 before recovering to $162.85.